Sensorineural hearing loss induced by gefitinib: A CARE-compliant case report and literature reviews

RATIONALE: Gefitinib is a potent and selective orally active growth factor receptor (EGFR)-tyrosine kinase inhibitor that is commonly used to treat advanced non-small cell lung cancer patients with activating EGFR mutations. Hearing impairment with gefitinib was sparsely reported. In this report, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Bao-chen, Yang, Wen-hua, Huang, Mao, Wang, Jin-gui, Liang, Yan, Lei, Zhen-zhen, Zhang, Sha-sha, Wang, Ying, Sun, Xiao-di, Gong, Ying, Xue, Chun-miao, Hua, Guo-dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637413/
https://www.ncbi.nlm.nih.gov/pubmed/37960757
http://dx.doi.org/10.1097/MD.0000000000036010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637413/
https://www.ncbi.nlm.nih.gov/pubmed/37960757
http://dx.doi.org/10.1097/MD.0000000000036010

Ejemplares similares